Europe Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Market Overview

The increasing burden of bladder cancer is the major factor driving the market in the European region. According to the estimates of Globocan, bladder cancer ranks fifth among the most frequently diagnosed cancer types, with about 197,105 new cases predicted in 2018 for both sexes, representing around 5% of the total cases. Moreover, increasing awareness about bladder cancer and related therapies is fueling the growth of the European bladder cancer therapeutics and diagnostics market. Apart from these, factors, like increasing awareness about bladder diseases and available therapies and innovations in novel drug development, are also contributing to the growth of the market studied. However, various factors, such as rise in the number of patent expiration is estimated to impede the growth of the studied market.

Scope of the Report

The bladder is a muscular membranous sack in the lower part of the abdomen that receives urine from the kidneys and stores it until it is excreted from the body. The most common type of bladder cancer is transitional cell carcinoma, which begins in the urothelial cells that line the inside of the bladder. Urothelial cells are transitional cells, which can change shape and stretch when the bladder is full. A common sign or symptom of bladder cancer is the release of blood along with the excreted urine. This type of cancer is also called urothelial carcinoma. Other types of bladder cancer include squamous cell carcinoma and adenocarcinoma. Bladder cancer can often be diagnosed at an early stage, and can be treated easily at this stage.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy Segment is Expected to Show Better Growth in the Forecast period.

Chemotherapeutics refers to the utilization of drugs to combat a certain disorder. Chemotherapy is the first choice for bladder cancer treatment. In bladder cancer, the drug is administered either intravesically or directly into the urinary bladder. The non-muscle invasive bladder cancer (NMIBC) treatment is generally performed by chemotherapy and BCG immunotherapy. There has not been much development on bladder cancer chemotherapeutic agents, during the past decade. Furthermore, the incidence of bladder cancer is high among the population, which is expected to drive the market over the forecast period.

To understand key trends, Download Sample Report